JAK Inhibitor Treatment in AGS

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03921554

Recruitment Status : Active, not recruiting

First Posted : April 19, 2019

Last Update Posted : July 21, 2022

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborator:

Eli Lilly and Company

Information provided by (Responsible Party):

Adeline Vanderver, MD, Children's Hospital of Philadelphia

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Estimated Primary Completion Date :	June 2025
Estimated Study Completion Date :	December 2025

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Adang LA, Gavazzi F, D'Aiello R, Isaacs D, Bronner N, Arici ZS, Flores Z, Jan A, Scher C, Sherbini O, Behrens EM, Goldbach-Mansky R, Olson TS, Lambert MP, Sullivan KE, Teachey DT, Witmer C, Vanderver A, Shults J. Hematologic abnormalities in Aicardi Goutieres Syndrome. Mol Genet Metab. 2022 Aug;136(4):324-329. doi: 10.1016/j.ymgme.2022.06.003. Epub 2022 Jun 16.

To Top